Key Insights• According to the research report, "South Korea Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the South Korea Point of Care Diagnostics Market was valued at more than 120 Million in 2025.• South Korea is leading a technological shift by integrating artificial intelligence directly into point-of-care (POC) testing platforms and software. A major clinical breakthrough includes Ministry of Food and Drug Safety (MFDS) approvals for AI-based diagnostic software (such as SpassageQ and AITRICS) that analyze real-time patient vital signs and biomarker signals at the bedside. These AI-enhanced POC platforms proactively predict acute critical conditions like sepsis, anaphylaxis, and hypovolemic shock hours before overt clinical deterioration, allowing emergency and ICU teams to intervene immediately.• Leveraging its advanced domestic biotechnology and microelectronics manufacturing capabilities, South Korea has accelerated the adoption of compact, benchtop nucleic acid amplification tests (NAAT) and microfluidic Lab-on-a-Chip platforms. Local diagnostic developers have perfected rapid isothermal PCR and microfluidic cartridges capable of detecting respiratory pathogens, oncology markers, and drug-resistant hospital infections within 15 to 20 minutes. This microfluidic efficiency eliminates centralized laboratory turnaround delays, enabling rapid triage in university hospital emergency departments and local health clinics.• South Korea is one of the world's fastest-aging societies, creating structural demand for decentralized chronic disease management across municipal health centers (Bo-gon-so) and senior care facilities. To manage the soaring prevalence of diabetes, cardiovascular disease, and chronic kidney conditions among the elderly, clinicians rely on multi-parametric point-of-care analyzers.

Portable electrochemical biosensors allow primary care physicians and visiting nurses to obtain quantitative readings for HbA1c, lipid panels, and cardiac biomarkers from a single finger-prick sample, adjusting chronic care regimens on site without requiring central laboratory visits.Market Outlook• The market outlook for point-of-care diagnostics in South Korea is strongly anchored by government-backed digital health modernization and national healthcare data unification. Under public digital health initiatives, modern POCT instruments deployed across hospitals, primary clinics, and long-term care facilities are being integrated into the national Electronic Health Record (EHR) and cloud platforms. This automated connectivity ensures that diagnostic results captured at the patient’s bedside automatically synchronize with hospital information systems (HIS), eliminating manual documentation errors and enabling real-time clinical monitoring across regional care networks.• Major domestic commercial developers and commercial diagnostic suppliers operating in South Korea include SD Biosensor, Seegene, Boditech Med, Humasis, Sugentech, JW Bioscience, Roche Diagnostics, and Abbott Laboratories, operating under medical device approval frameworks managed by the Ministry of Food and Drug Safety (MFDS) and supported by research guidance from the Korean Society for Laboratory Medicine (KSLM) and the Korea Medical Devices Industrial Cooperative Association (KMDICA).Market DynamicsDriver: Rapidly aging population and high healthcare accessSouth Korea is transitioning into a super-aged society at an unprecedented pace, driving a surge in chronic ailments (such as diabetes, cardiovascular conditions, and age-related illnesses). Backed by a universal, highly efficient National Health Insurance (NHI) system, patients and medical institutions readily adopt decentralized point-of-care (POC) testing to ensure early diagnosis and continuous management.Challenge: Intense price competition and strict local documentation hurdlesThe market is crowded with agile domestic diagnostic giants and global players, resulting in fierce pricing pressures, especially during public health tenders. Furthermore, navigating local technical dossiers, language requirements, and rigorous evaluation criteria set by health authorities creates considerable compliance overhead for foreign entrants.Trend: Convergence of advanced ICT, AI, and digital healthcare integrationSouth Korea is leveraging its world-class information and communications technology (ICT) infrastructure to embed artificial intelligence (AI) and cloud connectivity into POC diagnostic platforms. Modern portable diagnostic tools are increasingly designed to sync instantly with electronic medical records (EMRs) and digital health apps, supporting advanced remote patient monitoring and smart clinical workflows.Segment AnalysisSouth Korea Point of Care Diagnostics By Product• Glucose monitoring kits in South Korea are increasingly developing into connected diabetes-management systems rather than remaining simple meter-and-strip products.

Domestic manufacturers have established capabilities in Bluetooth-enabled meters and integrated monitoring ecosystems, while MFDS classifies glucose self-test strips as higher-risk IVD products, reflecting the clinical consequences of inaccurate results. This regulatory positioning makes accuracy, strip–meter compatibility, connectivity, and user-centered design important product characteristics.• Infectious-disease POC kits in South Korea span rapid immunological tests and increasingly sophisticated molecular diagnostics, with the technology selected according to the required balance between speed, specificity, and clinical consequence. MFDS places infectious-disease marker tests using immunological and molecular methods within higher-risk IVD classifications, which makes clinical-performance evidence and regulatory documentation particularly important.• Pregnancy and fertility testing is well suited to South Korea's consumer-oriented POC environment because users can obtain reproductive information privately without an initial laboratory visit. Product development increasingly extends beyond conventional pregnancy strips toward ovulation and fertility-window tests, digital readers, and formats designed for repeated home use. A particularly relevant development is MFDS's recent requirement framework for usability evidence for self-testing IVDs, which is intended to reduce errors by general consumers.• Hematology POC kits bring selected blood measurements closer to clinical decision-making through compact analyzers, cartridges, and simplified specimen workflows. Applications can include hemoglobin, coagulation-related parameters, and other blood measurements that can complement centralized laboratory testing.

In South Korea, the segment is shaped by MFDS's risk-based IVD classification and technical-document requirements, which consider intended use, mechanism of action, materials, performance, and clinical evidence where applicable.• Cardiometabolic monitoring kits in South Korea increasingly connect glucose, cholesterol, coagulation, and related measurements with longitudinal disease-management workflows. The distinctive direction is toward connected devices that can transmit results to smartphones or other digital platforms rather than leaving measurements isolated on the device. South Korea's regulatory environment is particularly relevant to this transition because MFDS has clarified requirements for cybersecurity documentation for IVD devices using wired or wireless communication.• Urinalysis testing kits are naturally suited to decentralized testing because urine collection is non-invasive and multi-parameter strips can provide preliminary information with minimal equipment. The segment ranges from visually interpreted strips to reader-assisted systems that standardize interpretation and electronically record results. South Korea's MFDS classification system explicitly places urine-chemistry IVD reagents in the lower-risk portion of its IVD framework compared with several infectious-disease and glucose self-testing categories.• Cholesterol test strips bridge conventional laboratory lipid testing and decentralized cardiometabolic screening by enabling measurements from small blood samples using compact readers. Their product differentiation increasingly centers on simple capillary collection, rapid processing, automated interpretation, and digital storage or transmission of results.

In South Korea, these products operate within the country's dedicated IVD regulatory framework, where classification is tied to intended use and risk.• Other Products include cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation assays, toxicology tests, reproductive biomarkers, and multi-analyte platforms. This segment is particularly suited to South Korea's technology-oriented diagnostics ecosystem because compact instruments can combine several assays with automated sample handling and digital result management. Emerging platforms can also incorporate software, wireless connectivity, and increasingly sophisticated interpretation functions. South Korea Point of Care Diagnostics By Technology/Platform• Lateral flow assays remain attractive for South Korean POC applications because they combine portability, rapid operation, and relatively simple workflows. They are particularly applicable to pregnancy, fertility, infectious-disease screening, and other rapid-test categories. Their evolution is increasingly toward improved analytical sensitivity, reader-assisted interpretation, multiplexing, and digitally recorded results rather than reliance solely on visual interpretation.• PCR and isothermal nucleic-acid amplification platforms are bringing molecular pathogen detection closer to the patient through compact analyzers and integrated cartridges. These systems can combine sample preparation, amplification, and detection into a controlled workflow, making them useful where pathogen-specific information is required rapidly.

South Korea's regulatory classification explicitly recognizes molecular infectious-disease marker tests as IVD products with meaningful clinical risk, so product developers need to demonstrate appropriate performance and clinical utility.• Microfluidics and immunoassays enable laboratory-like processes to be compressed into cartridges and compact analyzers. Microfluidic platforms can control small sample volumes and integrate preparation, reaction, separation, and detection, while immunoassays support biomarkers such as hormones, proteins, antigens, and antibodies. In South Korea, these technologies are well aligned with POC systems designed to provide more sophisticated testing outside conventional laboratories.• Dipsticks and test strips remain among the most accessible POC formats in South Korea because they require limited instrumentation and can be used close to the patient. Applications include glucose monitoring, urinalysis, pregnancy testing, fertility testing, and other screening procedures. Reader-assisted formats are increasingly adding automated interpretation and digital data capture to the traditional strip architecture. South Korea Point of Care Diagnostics By End-User• South Korean hospitals and critical-care centers use POC diagnostics where rapid measurements can complement centralized laboratory testing during acute clinical situations. Emergency departments, intensive-care units, operating environments, and other high-dependency settings can benefit from testing that reduces dependence on specimen transport and conventional laboratory turnaround.

The distinctive feature is integration with a formal IVD regulatory and quality system: MFDS requires appropriate approval, certification, or notification depending on risk and considers technical documentation and clinical evidence where applicable.• Clinical and diagnostic laboratories remain an important quality-management backbone for South Korean POC testing. Their functions can include method verification, quality control, calibration, operator training, troubleshooting, result review, and confirmation testing when appropriate. This role becomes more important as POC platforms adopt molecular diagnostics, immunoassays, microfluidics, and multi-analyte capabilities traditionally associated with centralized laboratories. • Home care and self-testing are important parts of South Korea's POC ecosystem, particularly for glucose, pregnancy, fertility, and selected cardiometabolic and infectious-disease applications. The defining characteristic is the transfer of specimen collection, testing, and initial interpretation to non-specialist users, making usability central to product performance. MFDS's 2026 regulatory amendment is particularly significant because it establishes a basis for requiring usability evidence for self-testing IVD reagents and instruments specifically to reduce consumer-use errors.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Point of Care Diagnostics Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Glucose Monitoring Kits• Infectious Diseases Testing Kits• Pregnancy And Fertility Testing Kits• Hematology Testing Kits• Cardiometabolic Monitoring Kits• Urinalysis Testing Kits• Cholesterol Test Strips• Other ProductsBy Technology/Platform• Lateral Flow Assays• Molecular Diagnostics (PCR/INAAT)• Microfluidics & Immunoassays• Dipsticks & Test StripsBy End-User• Hospitals & Critical Care Centers• Clinical & Diagnostic Laboratories• Home Care & Self-TestingBy Mode Of Purchase• Prescription Based Products• OTC ProductsBy Sample• Blood• Urine• Nasal and Oropharyngeal Swabs.